Sign In
Buy HIMS
$27.51
+0 (+0%)
At Close: Jun 03, 2026
Hims & Hers (HIMS) Gains 37.7% in Three Months: What's Next?
01:06pm, Friday, 05'th Jul 2024
Hims & Hers (HIMS) is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.
3 Stocks That Can Double Again in 2024
11:50am, Tuesday, 02'nd Jul 2024
Cava, Hims & Hers Health, and Sweetgreen have more than doubled in 2024. Cava and Sweetgreen should continue to benefit from the return to in-office workplaces.
Hims & Hers shares plunge 12% amid allegations of GLP-1 drug sourcing from ‘shady supplier'
04:31am, Monday, 01'st Jul 2024
Roughly a month after announcing that it would offer GLP-1 injectable weight-loss drugs comparable to the popular drugs Ozempic and Mounjaro, Hims & Hers Health shares are taking a beating after a new
Is Hims & Hers Stock a Buy After Short Report?
10:00am, Saturday, 29'th Jun 2024
There are valid points in the short report, but it may present a buying opportunity for long-term investors.
HIMS Stock Tumbles: Here's Why It's a Buy Right Now
04:00pm, Friday, 28'th Jun 2024
Hims & Hers Health is a high growth, healthcare startup stepping into the GLP-1 space.
Hims & Hers shares fall on Hunterbrook report that GLP-1 drugs come from 'shady supplier'
06:13pm, Thursday, 27'th Jun 2024
Sam Koppelman, Hunterbrook Media publisher and co-founder, joins 'Closing Bell Overtime' to talk its report that Hims & Hers' GLP-1 offering is a 'knockoff' drug form 'shady supplier'.
Hims & Hers Stock Drops 12.8% After Short Report
03:07pm, Thursday, 27'th Jun 2024
A short report was published that makes a case against Hims & Hers' new GLP-1 product. The report was put out by a media organization with ties to a fund that is also a short-seller of the stock.
Short Seller Hunterbrook Slams Hims & Hers (HIMS) Stock in New Report
11:28am, Thursday, 27'th Jun 2024
Hims & Hers Health (NYSE: HIMS ) stock is taking a tumble after Hunterbrook Media released a short report on the telehealth company. Hunterbrook operates an interesting business model, as it publishes
2 Top Growth Stocks to Buy With $500 Right Now
04:46am, Wednesday, 26'th Jun 2024
Consumer spending on healthcare and restaurants is resilient in a range of economic environments. Hims & Hers is tapping into the potential of the lucrative telehealth market.
Hims & Hers Health, Inc. (HIMS) Flat As Market Sinks: What You Should Know
06:50pm, Monday, 24'th Jun 2024
In the latest trading session, Hims & Hers Health, Inc. (HIMS) closed at $22.15, marking no change from the previous day.
Should You Buy Hims & Hers Health Stock Right Now?
09:37am, Monday, 24'th Jun 2024
The telehealth company is offering innovative products at lower prices.
5 Medical Info Systems Stock to Buy for a Stable Portfolio
09:20am, Monday, 24'th Jun 2024
We have narrowed our search to five medical info systems stocks. These are: HIMS, ENOV, LUNG, PHR, LAB.
3 Reasons to Buy Hims & Hers Health Stock Now
05:00pm, Thursday, 20'th Jun 2024
Summer has officially begun, but some stocks are receiving a chilly reception today.
Here is What to Know Beyond Why Hims & Hers Health, Inc. (HIMS) is a Trending Stock
10:05am, Wednesday, 19'th Jun 2024
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Hims & Hers: The Undervalued Gem Poised For Growth
03:05am, Tuesday, 18'th Jun 2024
As of this article being written, Hims & Hers Health is up around 33% since the announcement that they will offer GLP-1 Injections for as low as $199 a month. Reports that the company has already star
